Table 1.

Details of the MiHA profile of hematologic cancer patients after allogeneic stem cell transplantation

% expanded MiHA-specific CD8+ T cells
PatientDiseaseMiHA typePeptide% circulating MiHA-specific CD8+ T cellsLuci/mock DCLuci/IL15 DCPDL/mock DCPDL/IL15 DC
1MDS-RAEBHLA-B7 LRH1TPNQRQNVC0.0030.090.210.260.66
2AMLHLA-B7 LRH1TPNQRQNVC0.0120.600.680.680.76
3ALLHLA-A2 HA2YIGEVLVSV0.0110.400.620.530.99
4AMLHLA-B7 ARGHDIBLPRACWREA0.0260.840.821.091.10
5AMLHLA-B7 ARGHDIBLPRACWREA<0.0010.020.050.050.14
6CLLHLA-A2 HA1VLHDDLLEA0.0532.693.894.318.43
  • NOTE: Percentages are given of tetramer-positive MiHA-specific CD8+ T cells in peripheral blood (% circulating) and upon expansion in 7-day ex vivo cocultures with allogeneic designer DC (% expanded).

  • Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; CLL, chronic lymphoid leukemia; DC, dendritic cell; HLA, Human Leukocyte antigen; IL15, interleukin 15 mRNA electroporated; Luci, Luciferase siRNA lipofected; MDS-RAEB, Myelodysplastic Syndrome—Refractory Anemia with Excess of Blasts; mock, electroporated without mRNA; PDL, lipofected with siRNA silencing programmed death ligands.